Management ChangeMay 14, 2026, 04:40 PM
Hepion Pharmaceuticals Appoints New CEO; Reports Reduced Q1 Loss
AI Summary
Hepion Pharmaceuticals announced a significant leadership change with Dr. Kaouthar Lbiati resigning as CEO and Gary Stetz being appointed as the new CEO, alongside Vincent LoPriore as Executive Chairman. The company also reported a reduced net loss of $(0.81) million for Q1 2026, a substantial improvement from $(6.11) million in Q1 2025. This comes as the company pivots its focus from drug therapy to medical diagnostics, evidenced by a recent intellectual property license agreement with Cirna Diagnostics. Despite the improved financials, the company noted substantial doubt about its ability to continue as a going concern without additional capital, though it secured $700,000 in a private placement post-quarter end.
Key Highlights
- Gary Stetz appointed CEO and Vincent LoPriore Executive Chairman on May 5, 2026.
- Dr. Kaouthar Lbiati resigned as CEO on March 16, 2026, receiving $255,625 in severance and bonus.
- Q1 2026 net loss significantly reduced to $(0.81) million from $(6.11) million in Q1 2025.
- Net loss per common share improved to $(0.07) in Q1 2026 from $(2.15) in Q1 2025.
- Cash balance increased to $2.60 million at March 31, 2026, from $1.83 million at Dec 31, 2025.
- Licensed liver disease diagnostic assets from Cirna Diagnostics for $70,000 upfront, with potential milestones up to $6.85 million.
- Secured $700,000 gross proceeds from a private placement offering of common stock on April 21, 2026.
- Q1 2026 operating cash flow was $0.58 million, primarily due to a one-time $1.0 million insurance refund.